Welcome to our dedicated page for Canopy Growth SEC filings (Ticker: CGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ever tried locating Canopy Growth鈥檚 biological asset valuations or U.S. THC exposure in a 300-page report? The company鈥檚 cannabis regulations, fair-value accounting and brand acquisitions make each disclosure dense. That鈥檚 why this page does more than list documents鈥攊t turns the tough parts of Canopy Growth SEC filings explained simply.
Every form鈥攚hether a Canopy Growth quarterly earnings report 10-Q filing or a sudden Canopy Growth 8-K material events explained鈥攁rrives here within seconds of hitting EDGAR. Stock Titan鈥檚 AI instantly produces plain-English summaries, highlights cash-flow turning points and links note references so you can move from headline to footnote without scrolling hundreds of pages. Need to monitor management moves? Our alert engine captures Canopy Growth Form 4 insider transactions real-time, flagging each Canopy Growth executive stock transactions Form 4 alongside price and option data.
Use the annual report to see cultivation capacity; the proxy to unpack Canopy Growth proxy statement executive compensation; or dive into segment margins with our Canopy Growth earnings report filing analysis. If you are tracking regulatory risk, the system groups risk-factor language across years so understanding Canopy Growth SEC documents with AI becomes a two-minute task. Investors, analysts and portfolio managers rely on these tools to answer questions like 鈥淲hat did management say about U.S. legalization timing?鈥� or 鈥淲ere there new goodwill impairments?鈥濃�攁ll without manual page hunts. From the first Canopy Growth insider trading Form 4 transactions alert to a fully indexed Canopy Growth annual report 10-K simplified, every disclosure is refined for faster, smarter decision-making.
Canopy Growth Corporation (CGC) filed an 8-K reporting the immediate termination of Chief Financial Officer Judy Hong on 9 July 2025. The company states the dismissal was 鈥渨ithout cause鈥� and unrelated to its financial performance or reporting practices. Under the terms of her March 29 2022 employment agreement, Ms. Hong will receive all severance benefits applicable to a no-cause separation and a previously agreed US$150,000 retention bonus dated August 19 2024.
Interim leadership: Vice President, Finance Thomas Stewart, 43, has been appointed interim CFO effective the same day. Stewart has held finance leadership roles at Canopy since April 2019, including Chief Accounting Officer, and previously spent more than a decade at Constellation Brands. He is a CPA (NY) with extensive U.S. GAAP experience.
Compensation terms: An interim offer letter (Exhibit 10.1) grants Stewart an additional US$7,500 monthly stipend on top of his existing salary. His FY 2026 short-term incentive target will equal 75% of combined salary and stipend, prorated for his tenure as interim CFO.
Governance & disclosure: The company affirms there are no related-party transactions or family relationships involving either executive, and Item 7.01 furnishes a supporting press release (Exhibit 99.1). No financial statements accompany the filing.
While the board initiates a search for a permanent CFO, the internal appointment aims to ensure continuity across external reporting, FP&A, tax, and operations finance functions.
Form 8-K Highlights: Hyperion DeFi, Inc. (formerly Eyenovia, Inc.) filed a current report covering two principal matters: (1) departure of its Chief Operating Officer and (2) a corporate name and ticker change.
Executive departure (Item 5.02): Effective July 1, 2025, COO Bren Kern鈥檚 employment terminated in connection with a previously announced reduction-in-force. Under a Separation and Release Agreement, he will receive 12 months of base salary and up to 12 months of continued health-care benefits, conditioned upon standard release and covenant provisions. The agreement is attached as Exhibit 10.1.
Name and ticker change (Item 5.03): A Certificate of Amendment filed June 30, 2025, changed the company鈥檚 legal name from Eyenovia, Inc. to Hyperion DeFi, Inc., effective 8:00 a.m. ET on July 1, 2025. Board approval under Delaware General Corporation Law 搂242 was sufficient; no stockholder vote was required. Common shares retain the same rights and CUSIP, but the Nasdaq ticker will convert from 鈥淓YEN鈥� to 鈥淗YPD鈥� beginning July 3, 2025.
Reg FD disclosure (Item 7.01): A press release regarding the rebrand and ticker change was furnished (Exhibit 99.1) and is not deemed 鈥渇iled鈥� for Exchange Act liability.
Exhibits:
- 3.1 鈥� Certificate of Amendment (Name Change)
- 10.1 鈥� Separation and Release Agreement (COO)
- 99.1 鈥� Press Release announcing changes
- 104 鈥� Inline XBRL cover page
The filing is primarily administrative; it signals a strategic rebranding without altering share structure, while simultaneously disclosing senior management turnover that may raise continuity concerns.
The Form 4 filing reports that Chemours Company (CC) director Courtney Mather was awarded 2,292 deferred stock units (DSUs) on 30 June 2025. Each DSU equals one share of common stock and will be settled in the first month after the director leaves the board. The award is recorded at a reference price of $11.45 per unit. After the grant, Mather directly owns 2,292 derivative securities; no sales or additional purchases of common stock were disclosed. Apart from this routine director compensation grant, the filing contains no other material transactions or changes in ownership.
Dillard鈥檚, Inc. (DDS) Form 4 filing dated 07/02/2025 discloses a modest open-market purchase by long-time insider Drue Matheny, Executive Vice President and Director. On 06/30/2025 Matheny acquired 19 Class A common shares at $413.32 each, increasing her direct holding to 403,904 shares. She also continues to hold 36,648 shares through the company retirement plan and 9,821 shares indirectly (7,300 as trustee of the GST Trust and 2,521 held by her spouse). No derivative transactions were reported.
The purchase represents less than 0.005% of her direct ownership and is immaterial to DDS鈥檚 17 million share float, yet any insider buying鈥攑articularly by a senior executive鈥攎ay be interpreted as a confidence signal. There were no sales, option exercises, or 10b5-1 plan indications, and the filing confirms her continuing status as both officer and director.
FAQ
What is the current stock price of Canopy Growth (CGC)?
What is the market cap of Canopy Growth (CGC)?
What is Canopy Growth Corp's core business?
How does the company generate revenue?
What are the primary business segments of Canopy Growth?
How does Canopy Growth differentiate its products?
What role does innovation play at Canopy Growth?
How is Canopy Growth positioned in the U.S. market?
What challenges does the company face in the competitive cannabis industry?
How does Canopy Growth maintain trust and expertise in the industry?
